ClinicalTrials.gg
RecruitingNCT07161180PBK_M2301_BEUpdated Sep 12, 2025

Evaluation of the Pharmacokinetics of "PBK_M2301" in Healthy Adults

A Phase 1 interventional study of PBK_M2301 (levodropropizine + Pelargonium sidoides extract) and R1_PBK_M2301 (levodropropizine) in Healthy Volunteers, sponsored by Pharmbio Korea Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Pharmbio Korea Co., Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

The goal of this Phase 1 clinical trial is to evaluate the safety and pharmacokinetic characteristics of PBK_M2301 in healthy adult volunteers. The main questions it aims to answer are:

What are the maximum concentration (Cmax) and total drug exposure (AUCt) of PBK_M2301 compared to the combination of two reference drugs?

Are there any safety concerns associated with a single oral dose of PBK_M2301?

Researchers will compare PBK_M2301 with the combination of R1_PBK_M2301 and R2_PBK_M2301 to assess differences in drug levels.

Participants will:

Receive each treatment once in a randomized sequence with a one-week washout in between

Provide blood samples at multiple time points after dosing

Undergo safety assessments including adverse event monitoring, vital signs, laboratory tests, and ECGs

Read the detailed description

This Phase 1, open-label, randomized, two-period, two-sequence crossover study will evaluate the safety and pharmacokinetic characteristics of PBK_M2301 in 32 healthy adults. PBK_M2301 contains levodropropizine 60 mg and Pelargonium sidoides extract 20 mg per tablet.

Participants will receive either a single dose of PBK_M2301 or a combination of two reference drugs (R1_PBK_M2301 and R2_PBK_M2301) in a randomized sequence, with a one-week washout between treatments. Blood samples will be collected at multiple time points up to 12 hours post-dose to determine plasma concentrations of levodropropizine using a validated LC-MS/MS method.

Primary endpoints are Cmax and AUCt, with secondary endpoints including AUC∞, Tmax, t1/2, CL/F, and Vz/F. Safety will be assessed by monitoring adverse events, vital signs, laboratory tests, and ECGs throughout the study.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pharmacokinetics
03

In context

Lead sponsor

Pharmbio Korea Co., Ltd. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet all of the following criteria may be included in the study:

  1. Male or female subjects aged 19 years or older and less than 65 years at the time of screening.
  2. (BMI) between 18 and 30 kg/m² (inclusive) at screening (BMI = weight (kg) / height (m)²):

    • For male subjects: body weight ≥ 50 kg.
    • For female subjects: body weight ≥ 45 kg.
  3. No congenital or chronic diseases, and no pathological symptoms or findings based on internal medicine examination (including, if necessary, electroencephalography, electrocardiography, chest and/or upper gastrointestinal endoscopy, or gastrointestinal radiographic examination).
  4. Judged by the principal investigator (or a sub-investigator) to be suitable for participation based on diagnostic tests performed according to the characteristics of the product, including hematology, clinical chemistry, coagulation, serology, urinalysis, and electrocardiography ().
  5. Voluntarily decides to participate after receiving and fully understanding a detailed explanation of the study, and signs the written form, agreeing to comply with the study requirements during the study period.
  6. Agrees to use medically acceptable * (excluding hormonal contraceptives) from the first administration of the investigational product until 1 week after the last administration, to prevent pregnancy in themselves or their spouse/partner, and agrees not to donate sperm or ova during this period.

    • Medically acceptable contraception: intrauterine device (IUD), intrauterine system (IUS), vasectomy, tubal ligation, or a combination of barrier methods (male condom, female condom, cervical cap, diaphragm, contraceptive sponge). When using spermicide, at least two barrier methods should be used in combination.

Exclusion criteria

2 Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study:

  1. Use of enzyme-inducing or enzyme-inhibiting drugs such as barbiturates within 30 days prior to the first administration, or use of any drugs that may interfere with the study within 10 days prior to the first administration.
  2. Participation in a bioequivalence study or any other clinical trial and administration of an product within 6 months prior to the first administration in this study.
  3. Whole blood donation within 8 weeks, component blood donation within 2 weeks, or receipt of a blood transfusion within 4 weeks prior to the first administration in this study.
  4. History of gastrointestinal resection surgery that may affect drug absorption (excluding appendectomy or hernia repair).
  5. Within 1 month prior to the first administration:

    • For male subjects: average alcohol consumption > 21 units/week.
    • For female subjects: average alcohol consumption > 14 units/week.

      (1 unit = 50 mL soju, 250 mL beer, or 30 mL whisky)

    • Average smoking > 20 cigarettes/day.
  6. Presence of the following conditions:

    • Known to the investigational product or any of its components.
    • Bronchial hypersecretion.
    • Mucociliary dysfunction (e.g., Kartagener syndrome, primary ciliary dyskinesia).
    • Increased bleeding tendency or use of anticoagulant therapy.
    • Severe hepatic impairment.
    • Severe liver disease or severe renal disease.
    • Hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  7. History of psychiatric disorders.
  8. Any other reason, not specified in the inclusion/exclusion criteria, that in the opinion of the principal investigator (or a sub-investigator) makes the subject unsuitable for participation.
  9. For female subjects: pregnant, suspected of being pregnant, or breastfeeding.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Active comparator
    Arm 1: R1_PBK_M2301 + R2_PBK_M2301 Followed by PBK_M2301

    Participants in this arm will receive a single oral dose of R1\_PBK\_M2301 (levodropropizine 60 mg) plus R2\_PBK\_M2301 (Pelargonium sidoides extract 20 mg) in Period 1, followed by a one-week washout, and then a single oral dose of PBK\_M2301 (levodropropizine 60 mg + Pelargonium sidoides extract 20 mg) in Period 2. All doses will be administered after at least 10 hours of fasting, with 150 mL of water at room temperature.

    Drug: PBK_M2301 (levodropropizine + Pelargonium sidoides extract) · Drug: R1_PBK_M2301 (levodropropizine) · Drug: R2_PBK_M2301 (Pelargonium sidoides extract)

  • Experimental
    Arm 2: PBK_M2301 Followed by R1_PBK_M2301 + R2_PBK_M2301

    Participants in this arm will receive a single oral dose of PBK\_M2301 (levodropropizine 60 mg + Pelargonium sidoides extract 20 mg) in Period 1, followed by a one-week washout, and then a single oral dose of R1\_PBK\_M2301 (levodropropizine 60 mg) plus R2\_PBK\_M2301 (Pelargonium sidoides extract 20 mg) in Period 2. All doses will be administered after at least 10 hours of fasting, with 150 mL of water at room temperature.

    Drug: PBK_M2301 (levodropropizine + Pelargonium sidoides extract) · Drug: R1_PBK_M2301 (levodropropizine) · Drug: R2_PBK_M2301 (Pelargonium sidoides extract)

Interventions

  • DrugPBK_M2301 (levodropropizine + Pelargonium sidoides extract)

    A single oral tablet containing levodropropizine 60 mg and Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.

    Also known as: PBK_M2301

  • A single oral tablet containing levodropropizine 60 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.

    Also known as: R1_PBK_M2301

  • DrugR2_PBK_M2301 (Pelargonium sidoides extract)

    A single oral tablet containing Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.

    Also known as: R2_PBK_M2301

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of Levodropropizine

    Cmax will be determined from plasma concentration-time data following single and multiple oral doses of PBK\_M2301, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.

    Time frame: Pre-dose (0 hours) to 12 hours post-dose (depending on dosing regimen)

  2. Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUCt) of Levodropropizine

    AUCt will be calculated using the linear trapezoidal method based on plasma concentration-time data, in accordance with "Regulations on Bioequivalence Tests" (Article 17).

    Time frame: Pre-dose (0 hours) to 12 hours post-dose (depending on dosing regimen)

Secondary outcomes

  1. Area under the plasma concentration-time curve extrapolated to infinity (AUC∞) of Levodropropizine

    AUC∞ will be derived as the sum of AUCt and the extrapolated terminal area (Ct/λZ) using noncompartmental analysis, following single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.

    Time frame: Pre-dose (0 hours) to last quantifiable concentration plus extrapolated terminal phase (up to 12 hours post-dose)

  2. Ratio of AUCt to AUC∞ of Levodropropizine

    The percentage of AUCt relative to AUC∞ will be calculated for each participant to assess the proportion of the observed exposure, following single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.

    Time frame: Pre-dose (0 hours) to last quantifiable concentration plus extrapolated terminal phase (up to 12 hours post-dose)

  3. Time to reach maximum plasma concentration (Tmax) of Levodropropizine

    Tmax will be recorded as the actual observed time of maximum plasma concentration for each participant after single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.

    Time frame: Pre-dose (0 hours) to 12 hours post-dose

  4. Terminal elimination half-life (t1/2) of Levodropropizine

    t1/2 will be estimated from the terminal slope of the log-linear portion of the plasma concentration-time curve after single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.

    Time frame: From Cmax to terminal phase (up to 12 hours post-dose)

  5. Apparent oral clearance (CL/F) of Levodropropizine

    CL/F will be calculated as the ratio of dose to AUC∞ using noncompartmental methods, following single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.

    Time frame: From dosing to terminal phase (up to 12 hours post-dose)

  6. Apparent volume of distribution (Vz/F) of Levodropropizine

    Vz/F will be estimated using noncompartmental analysis based on plasma concentration-time data following single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.

    Time frame: From dosing to terminal phase (up to 12 hours post-dose)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to internal policy and data protection regulations. The dataset is limited to a small population of healthy volunteers and is intended solely for internal analysis and regulatory submission.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Oct 2025, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Sep 8, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Oct 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07161180
Lead sponsor
Pharmbio Korea Co., Ltd.
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Aug 27, 2025
Primary completion
Oct 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Sep 12, 2025

Study contacts

Manager Clinical Trial Team, Pharmbio Korea NA
Contact
cr@pharmbio.co.kr
+92-2-587-2551

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dipropizine

Start the discussion